Kurzfassung

A phase III, randomized, multi-center, open-label, comparative global study to determine the efficacy of Durvalumab or Durvalumab and Tremelimumab in combination with platinum-based chemotherapy for first-line Treatment in patients with metastatic Non-Small-Cell Lung
Cancer